CML exposure markedly increased Bax expression and decreased Bcl-2 expression (p < 0.001 vs. control), resulting in a reduced Bcl-2/Bax ratio. The gene discussed is BAX; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.